https://sputnikglobe.com/20200918/russian-developer-of-covid-drug-areplivir-discussing-deliveries-to-latin-america-africa-1080505930.html
Russian Developer of COVID Drug Areplivir Discussing Deliveries to Latin America, Africa
Russian Developer of COVID Drug Areplivir Discussing Deliveries to Latin America, Africa
Sputnik International
MOSCOW (Sputnik) - Russian pharmaceutical company Promomed is in talks with neighbouring countries, Latin America, and Africa to supply them with Areplivir... 18.09.2020, Sputnik International
2020-09-18T15:39+0000
2020-09-18T15:39+0000
2020-09-18T15:39+0000
https://cdn1.img.sputnikglobe.com/img/07e4/09/12/1080505895_0:130:3072:1868_1920x0_80_0_0_f974947a55dd69d9b10f0af07e2a74b7.jpg
russia
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2020
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
russia introduces first coronavirus vaccine, newsfeed, society, russia, coronavirus
russia introduces first coronavirus vaccine, newsfeed, society, russia, coronavirus
Russian Developer of COVID Drug Areplivir Discussing Deliveries to Latin America, Africa
MOSCOW (Sputnik) - Russian pharmaceutical company Promomed is in talks with neighbouring countries, Latin America, and Africa to supply them with Areplivir drug that can help in the COVID-19 treatment, the director-general of the company, Andrey Mladentsev, said.
"We are in talks about the delivery of the medication to the countries of Latin America, such as Mexico, South Africa and Commonwealth of Independent States," Mladentsev said.
According to Mladentsev, Areplivir will be available in internet pharmacies in Russia on Saturday and may appear on the shelves of regular pharmacies in Moscow on Monday.
"The recommended price is 12,320 rubles [$164]," he said.
According to the company's head, the price is unlikely to change significantly in the near future.
Areplivir was approved by the Russian Health Ministry in late June.
